{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T09:16:00Z","timestamp":1772356560222,"version":"3.50.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T00:00:00Z","timestamp":1715731200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T00:00:00Z","timestamp":1715731200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1038\/s41375-024-02242-6","type":"journal-article","created":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T13:02:35Z","timestamp":1715778155000},"page":"1564-1569","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Chimeric antigen receptor T-cell infusion for large B-cell lymphoma in complete remission: a center for international blood and marrow transplant research analysis"],"prefix":"10.1038","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5685-7204","authenticated-orcid":false,"given":"Trent P.","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kwang W.","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mazyar","family":"Shadman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manmeet","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4336-4982","authenticated-orcid":false,"given":"Nausheen","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrike","family":"Bacher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Cerny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5204-9445","authenticated-orcid":false,"given":"Andy","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8216-3457","authenticated-orcid":false,"given":"Narendranath","family":"Epperla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Frigault","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalie","family":"Grover","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0056-6023","authenticated-orcid":false,"given":"Bradley","family":"Haverkos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Hill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3278-655X","authenticated-orcid":false,"given":"Nasheed","family":"Hossain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madiha","family":"Iqbal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6854-773X","authenticated-orcid":false,"given":"Tania","family":"Jain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maxwell M.","family":"Krem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1732-6694","authenticated-orcid":false,"given":"Joseph","family":"Maakaron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6525-8844","authenticated-orcid":false,"given":"Dipenkumar","family":"Modi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8582-1219","authenticated-orcid":false,"given":"Muhamad","family":"Alhaj Moustafa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Riedell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3304-9965","authenticated-orcid":false,"given":"Bipin","family":"Savani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. Alejandro","family":"Sica","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1238-6970","authenticated-orcid":false,"given":"Anna","family":"Sureda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9528-8681","authenticated-orcid":false,"given":"Kitsada","family":"Wudhikarn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9665-7415","authenticated-orcid":false,"given":"Alex F.","family":"Herrera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig","family":"Sauter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5372-510X","authenticated-orcid":false,"given":"Mehdi","family":"Hamadani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2817-6836","authenticated-orcid":false,"given":"Antonio","family":"Jimenez Jimenez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,5,15]]},"reference":[{"key":"2242_CR1","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1056\/NEJMra2027612","volume":"384","author":"LH Sehn","year":"2021","unstructured":"Sehn LH, Salles G. Diffuse large B-cell lymphoma. N Engl J Med. 2021;384:842\u201358.","journal-title":"N Engl J Med"},{"key":"2242_CR2","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jtct.2023.07.002","volume":"29","author":"AS Kanate","year":"2023","unstructured":"Kanate AS, Majhail N, DeFilipp Z, Dhakal B, Dholaria B, Hamilton B, et al. Updated indications for immune effector cell therapy: 2023 guidelines from the American society for transplantation and cellular therapy. Transpl Cell Ther. 2023;29:594\u20137.","journal-title":"Transpl Cell Ther"},{"key":"2242_CR3","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/j.bbmt.2020.03.002","volume":"26","author":"AS Kanate","year":"2020","unstructured":"Kanate AS, Majhail NS, Savani BN, Bredeson C, Champlin RE, Crawford S, et al. Indications for hematopoietic cell transplantation and immune effector cell therapy: guidelines from the american society for transplantation and cellular therapy. Biol Blood Marrow Transpl. 2020;26:1247\u201356.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2242_CR4","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-Cell therapy in refractory large B-cell lymphoma. N. Engl J Med. 2017;377:2531\u201344.","journal-title":"N. Engl J Med"},{"key":"2242_CR5","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N. Engl J Med. 2018;378:439\u201348.","journal-title":"N. Engl J Med"},{"key":"2242_CR6","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","volume":"396","author":"Abramson","year":"2020","unstructured":"Abramson, Palomba JS, Gordon LI ML, Lunning MA, Wang M, Arnason J, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396:839\u201352.","journal-title":"Lancet"},{"key":"2242_CR7","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJMoa2301665","volume":"389","author":"JR Westin","year":"2023","unstructured":"Westin JR, Oluwole OO, Kersten MJ, Miklos DB, Perales MA, Ghobadi A, et al. Survival with axicabtagene ciloleucel in large B-cell lymphoma. N Engl J Med. 2023;389:148\u201357.","journal-title":"N Engl J Med"},{"key":"2242_CR8","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.jtct.2023.06.012","volume":"29","author":"N Epperla","year":"2023","unstructured":"Epperla N, Kumar A, Abutalib SA, Awan FT, Chen YB, Gopal AK, et al. ASTCT clinical practice recommendations for transplantation and cellular therapies in diffuse large B cell lymphoma. Transpl Cell Ther. 2023;29:548\u201355.","journal-title":"Transpl Cell Ther"},{"key":"2242_CR9","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1188\/19.CJON.S2.27-30","volume":"23","author":"A Beaupierre","year":"2019","unstructured":"Beaupierre A, Lundberg R, Marrero L, Jain M, Wang T, Alencar MC. Management across settings: an ambulatory and community perspective for patients undergoing CAR T-cell therapy in multiple care settings. Clin J Oncol Nurs. 2019;23:27\u201334.","journal-title":"Clin J Oncol Nurs"},{"key":"2242_CR10","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.3324\/haematol.2022.281954","volume":"108","author":"AP Jallouk","year":"2023","unstructured":"Jallouk AP, Gouni S, Westin J, Feng L, Mistry H, Steiner RE, et al. Axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma patients in complete metabolic response. Haematologica. 2023;108:1163\u20137.","journal-title":"Haematologica"},{"key":"2242_CR11","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1182\/bloodadvances.2019000151","volume":"3","author":"MR Bishop","year":"2019","unstructured":"Bishop MR, Maziarz RT, Waller EK, Jager U, Westin JR, McGuirk JP, et al. Tisagenlecleucel in relapsed\/refractory diffuse large B-cell lymphoma patients without measurable disease at infusion. Blood Adv. 2019;3:2230\u20136.","journal-title":"Blood Adv"},{"key":"2242_CR12","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1182\/bloodadvances.2022008294","volume":"7","author":"K Wudhikarn","year":"2023","unstructured":"Wudhikarn K, Tomas AA, Flynn JR, Devlin SM, Brower J, Bachanova V, et al. Low toxicity and excellent outcomes in patients with DLBCL without residual lymphoma at the time of CD19 CAR T-cell therapy. Blood Adv. 2023;7:3192\u20138.","journal-title":"Blood Adv"},{"key":"2242_CR13","doi-asserted-by":"crossref","unstructured":"Landsburg DJ, Frigault M, Heim M, Foley SR, Hill BT, Ho CM, et al. Real-world outcomes for patients with relapsed or refractory (R\/R) aggressive B-cell non-hodgkin\u2019s lymphoma (aBNHL) treated with commercial tisagenlecleucel: subgroup analyses from the Center for International Blood and Marrow Transplant Research (CIBMTR) registry. Blood. 2022;140:S1584\u20137.","DOI":"10.1182\/blood-2022-158822"},{"key":"2242_CR14","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1182\/bloodadvances.2020002394","volume":"4","author":"FL Locke","year":"2020","unstructured":"Locke FL, Rossi JM, Neelapu SS, Jacobson CA, Miklos DB, Ghobadi A, et al. Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv. 2020;4:4898\u2013911.","journal-title":"Blood Adv"},{"key":"2242_CR15","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579\u201386.","journal-title":"J Clin Oncol"},{"key":"2242_CR16","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059\u201368.","journal-title":"J Clin Oncol"},{"key":"2242_CR17","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transpl. 2019;25:625\u201338.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2242_CR18","doi-asserted-by":"crossref","first-page":"581.e1","DOI":"10.1016\/j.jtct.2022.05.026","volume":"28","author":"CA Jacobson","year":"2022","unstructured":"Jacobson CA, Locke FL, Ma L, Asubonteng J, Hu ZH, Siddiqi T, et al. Real-world evidence of axicabtagene ciloleucel for the treatment of large B cell lymphoma in the United States. Transpl Cell Ther. 2022;28:581.e1\u2013e8.","journal-title":"Transpl Cell Ther"},{"key":"2242_CR19","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.19.02104","volume":"38","author":"LJ Nastoupil","year":"2020","unstructured":"Nastoupil LJ, Jain MD, Feng L, Spiegel JY, Ghobadi A, Lin Y, et al. Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US Lymphoma CAR T Consortium. J Clin Oncol. 2020;38:3119\u201328.","journal-title":"J Clin Oncol"},{"key":"2242_CR20","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1002\/cam4.3881","volume":"10","author":"G Iacoboni","year":"2021","unstructured":"Iacoboni G, Villacampa G, Martinez-Cibrian N, Bailen R, Lopez Corral L, Sanchez JM, et al. Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma. Cancer Med. 2021;10:3214\u201323.","journal-title":"Cancer Med"},{"key":"2242_CR21","first-page":"2307","volume":"141","author":"SS Neelapu","year":"2023","unstructured":"Neelapu SS, Jacobson CA, Ghobadi A, Miklos DB, Lekakis LJ, Oluwole OO, et al. Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood. 2023;141:2307\u201315.","journal-title":"Blood"},{"key":"2242_CR22","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1182\/blood.2021013289","volume":"139","author":"M Shadman","year":"2022","unstructured":"Shadman M, Pasquini M, Ahn KW, Chen Y, Turtle CJ, Hematti P, et al. Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission. Blood. 2022;139:1330\u20139.","journal-title":"Blood"},{"key":"2242_CR23","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1182\/bloodadvances.2021005788","volume":"6","author":"M Hamadani","year":"2022","unstructured":"Hamadani M, Gopal AK, Pasquini M, Kim S, Qiu X, Ahmed S, et al. Allogeneic transplant and CAR-T therapy after autologous transplant failure in DLBCL: a noncomparative cohort analysis. Blood Adv. 2022;6:486\u201394.","journal-title":"Blood Adv"},{"key":"2242_CR24","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/j.bbmt.2014.06.036","volume":"20","author":"M Hamadani","year":"2014","unstructured":"Hamadani M, Hari PN, Zhang Y, Carreras J, Akpek G, Aljurf MD, et al. Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantation. Biol Blood Marrow Transpl. 2014;20:1729\u201336.","journal-title":"Biol Blood Marrow Transpl"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02242-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02242-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02242-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T23:07:55Z","timestamp":1719875275000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02242-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,15]]},"references-count":24,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["2242"],"URL":"https:\/\/doi.org\/10.1038\/s41375-024-02242-6","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,15]]},"assertion":[{"value":"15 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"TPW reports consultancy for: Kite\/a Gilead Company, Incyte, Sanofi. He has received research funding from: Syndax\/Incyte, AlloVir, Kadmon\/Sanofi. MS reports consultancy for: AbbVie, Genentech, AstraZeneca, Pharmacyclics, BeiGene, BMS, MorphoSys\/Incyte, Kite, Eli Lilly, Genmab, Mustang Bio, Regeneron, ADC therapeutics, Fate Therapeutics, Janssen and MEI Pharma. He receives research funding: Mustang Bio, BMS, Pharmacyclics, Genentech, AbbVie,TG Therapeutics, BeiGene, AstraZeneca, Genmab, MorphoSys\/Incyte, Vincerx. NA reports institutional research funding and consultancy fees from Kite\/Gilead; and advisory board funds from Bristol Myers Squibb. JC reports consultancy for: Bristol Myers Squibb and Merit CRO. He serves as a data safety monitoring board member with ICON-Allovir and ICON-Prolacta. He owns stock in Actinium Pharmaceuticals, Bluebird Bio\/2Seventy, Dynavax Technologies, aTyr Pharma, Gamida Cell Ltd, Novavax Inc, Ovid Therapeutics, Vaxart, and Veru. AC reports consultancy for: Elsevier, Kite and research funding from: Novartis, Fate Therapeutics, Kite, BMS. MJF reports consulting and advisory roles for Kite\/Gilead, BMS, Novartis, JnJ\/Legend. He reports research funding from Arcellx, Kite\/Gilead, Novartis, Incyte. NG reports Honoraria from: Novartis, Kite, BMS, Caribou, Genentech, Janssen, Seagen, ADC Therapeutics. Brian Hill reports research funding and consultancy from Gilead, Novartis and BMS. TJ receives institutional research funding from\u201d CTI Biopharma, Kartos therapeutics, Incyte, Bristol Myers Squibb; Advisory board participation with: Care Dx, Bristol Myers Squibb, Incyte, Abbvie, CTI, Kite, Cogent Biosciences, Blueprint Medicine, Telios pharma, Protagonist therapeutics; Education activity with Oncology APP, Binaytara Foundation, and ASH Highlights. JEM reports: research funding from Gilead, Atara, CRISPR, Precision Biosciences, and Scripps Research Institute. Dipenkumar Modi reports research funding from: Genentech, ADC Therapeutics, Karyopharm Therapeutics, Genmab. Consultancy: SeaGen, MorphoSys, ADC Therapeutics, Genmab. Honorarium: AstraZeneca, Beigene. MM reports consultancy from: AbbVie, CSL Behring. Peter Riedell reports consultancy and\/or advisory board member for AbbVie, Novartis, BMS, ADC Therapeutics, Kite\/Gilead, Sana Biotechnology, Nektar Therapeutics, NurixTherapeutics, Intellia Therapeutics, CVS Caremark, Genmab, BeiGene, Janssen, and Pharmacyclics. He has received honoraria from Novartis. Research support from BMS, Kite Pharma, Novartis, MorphoSys, CRISPR Therapeutics, Calibr, Xencor, Fate Therapeutics, AstraZeneca, Genentech, and Tessa Therapeutics. AS report Consultancy: Takeda, BMS\/Celgene, Novartis, Janssen, Gilead, Sanofi. Research support: Takeda, BMS\/Celgene.Honoraria: Takeda, BMS\/Celgene, MSD, Janssen, Amgen, Novartis, Gilead Kite, Sanofi, Roche, Alexion. Speaker\u2019s Bureau: Takeda. AH reports consultancy from: Bristol Myers Squibb, Genentech, Merck, Seattle Genetics, AstraZeneca, ADC Therapeutics, Takeda, Tubulis, Regeneron, Genmab, Pfizer, Caribou Biosciences, Adicet Bio, AddVie, Allogene Therapeutics. He reports research funding from: Bristol Myers Squibb, Genenetech, Merck, Seattle Genetics, KiTE Pharma, Gilead Sciences, AstraZeneca, ADC Therapeutics. CS has served as a paid consultant: Kite\/a Gilead Company, Celgene\/BMS, Gamida Cell, Karyopharm Therapeutics, Ono Pharmaceuticals, MorphoSys, CSL Behring, Syncopation Life Sciences, CRISPR Therapeutics and GSK. He has received research funds for clinical trials from: Juno Therapeutics, Celgene\/BMS, Bristol-Myers Squibb, Precision Biosciences, Actinium Pharmaceuticals, Sanofi-Genzyme and NKARTA. Mehdi Hamadani reports research support\/Funding: Takeda Pharmaceutical Company; ADC Therapeutics; Spectrum Pharmaceuticals; Astellas Pharma. Consultancy: ADC Therapeutics, Omeros, CRISPR, BMS, Kite, Abbvie, Caribou, Genmab. Speaker\u2019s Bureau: ADC Therapeutics, AstraZeneca, BeiGene, Kite. DMC: Inc, Genentech, Myeloid Therapeutics, CRISPR. AJJ reports: research funding AbbVie. The other authors reported no conflicts of interest to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}